Shares of Champions Oncology Inc (NASDAQ:CSBR) dropped 4.9% during mid-day trading on Friday . The stock traded as low as $12.75 and last traded at $12.25. Approximately 38,821 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 251,416 shares. The stock had previously closed at $12.88.
CSBR has been the topic of several recent research reports. Zacks Investment Research raised shares of Champions Oncology from a “hold” rating to a “strong-buy” rating and set a $12.00 price target on the stock in a report on Monday. Craig Hallum initiated coverage on shares of Champions Oncology in a report on Tuesday, July 17th. They issued a “buy” rating and a $12.00 price target on the stock. Janney Montgomery Scott initiated coverage on shares of Champions Oncology in a research note on Monday, July 9th. They set a “buy” rating on the stock. Finally, ValuEngine raised shares of Champions Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, June 5th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Champions Oncology currently has a consensus rating of “Buy” and a consensus price target of $11.33.
The company has a current ratio of 0.73, a quick ratio of 0.68 and a debt-to-equity ratio of 0.23. The company has a market cap of $156.08 million, a PE ratio of -92.21 and a beta of 0.12.
Champions Oncology (NASDAQ:CSBR) last announced its quarterly earnings data on Thursday, September 13th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. The business had revenue of $6.23 million for the quarter, compared to the consensus estimate of $5.85 million. Champions Oncology had a negative net margin of 1.63% and a negative return on equity of 97.02%. analysts anticipate that Champions Oncology Inc will post 0.12 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in CSBR. BlackRock Inc. acquired a new position in Champions Oncology during the second quarter worth approximately $104,000. Renaissance Technologies LLC increased its position in Champions Oncology by 63.3% during the second quarter. Renaissance Technologies LLC now owns 100,600 shares of the biotechnology company’s stock worth $638,000 after purchasing an additional 39,000 shares during the last quarter. Essex Investment Management Co. LLC acquired a new position in Champions Oncology during the second quarter worth approximately $646,000. Perkins Capital Management Inc. acquired a new position in Champions Oncology during the second quarter worth approximately $653,000. Finally, Tocqueville Asset Management L.P. acquired a new position in Champions Oncology during the second quarter worth approximately $729,000. 38.94% of the stock is currently owned by institutional investors and hedge funds.
Champions Oncology Company Profile (NASDAQ:CSBR)
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.